Neuraxis

NeurAxis is a growth-stage company focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. NeurAxis is committed to advancing scientific development through its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. With one FDA-approved indication already on the market, additional clinical trials for PENFS are underway across various pediatric conditions, focusing on unmet healthcare needs in children. NeurAxis’s mission is to provide solutions that create value and deliver better, safer patient outcomes. NeurAxis has received market approval for its first therapy, IB-Stim, targeting pediatric functional abdominal pain associated with IBS, addressing a total pediatric market of up to 6 million. The FDA has approved NeurAxis’s IB-Stim therapy for treating pediatric functional abdominal pain related to IBS. IB-Stim is a non-surgical device that works by delivering mild electrical pulses to the cranial nerve bundle located in the ear. This stimulation targets brain regions involved in pain processing and helps reduce functional abdominal pain associated with irritable bowel syndrome (IBS). Founded in 2011, NeurAxis has offices in Versailles, Indiana, and Carmel, Indiana, and is dedicated to increasing awareness and accessibility of this breakthrough technology among children.